What Is an FDA Advisory Committee Meeting (and Why Do Biotech Stocks Move on It)?

• →The FDA announces a meeting date, usually weeks ahead.
• →About two business days before the meeting, the FDA posts briefing documents: its own review of the data and the sponsor's.
• →The panel meets, debates, and votes on questions the FDA sets.
• →The FDA decides on or before the target date, sometimes months later.

The FDA's briefing document is the first time the public sees the agency's own read of the trial. If the reviewers write that the drug "did not meet" its endpoint, or flag a safety concern, the stock reprices on that day, before anyone votes. A negative briefing document can cut a small biotech in half in a session. A positive one removes the main risk.

InsiderWatch reads the FDA's advisory-committee materials table continuously, pulls the verdict language out of new briefing documents, and alerts on the document drop, not only on the later vote or press release.

Votes are reported as counts for and against on each question. A split vote with a narrow margin often leads to a complete-response letter or a narrower label. Unanimous votes in either direction are usually followed by the FDA.

The FDA runs standing advisory committees by therapeutic area: oncologic drugs (ODAC), cardiovascular and renal drugs, psychopharmacologic drugs, antimicrobial drugs, vaccines (VRBPAC), and others, plus device panels. Members are outside clinicians and statisticians with consumer and industry representatives. The FDA decides whether to convene a committee for a given application; it is not required to, and in recent years it has held fewer meetings and decided more applications on its own review. When a meeting is called, it is usually because the application is close, novel, or contested.

• →Federal Register notice and the FDA meeting page: the date, the committee, the drug and the sponsor. Often the first public confirmation of the review timeline.
• →FDA briefing document: the agency reviewers' own analysis of efficacy and safety, posted about two business days before the meeting. This is the document that moves the stock.
• →Sponsor briefing document: the company's version, posted alongside.
• →Draft questions to the committee: what the panel will vote on, which tells you what the FDA is worried about.
• →The meeting itself, webcast, with the vote counts released the same day.
• →The FDA's decision on or before the PDUFA target date, weeks to months later: approval, or a complete response letter listing what the company must fix.

The document opens by restating the legal standard, "substantial evidence of effectiveness", and that language appears in every one, positive or negative. The signal is deeper in: whether the primary endpoint was met with statistical significance, whether the FDA's own analysis agrees with the sponsor's, whether a safety signal is described as a "concern", and whether the reviewers write that the benefit-risk balance is favorable. Phrases like "did not demonstrate", "no statistically significant", "uncertain clinical meaningfulness" and "safety concern" in the FDA's executive summary are the verdict; the company's document will say the opposite of each, and the market reads the FDA's.

InsiderWatch extracts exactly those passages from new briefing documents as they post and alerts on the language, because the drop is the event: a negative FDA briefing document has cut a single-drug biotech in half before the panel ever met.

The FDA usually follows the committee but is not bound by it. A lopsided positive vote followed by approval on the PDUFA date is the normal path. A split or negative vote most often leads to a complete response letter, sometimes to approval with a narrower indication or a boxed warning. A meeting that is cancelled at short notice is read as the FDA no longer needing advice, which is positive when the review was going well and ambiguous otherwise. The PDUFA date itself is public and is the next binary event on the calendar; InsiderWatch records stated PDUFA and meeting dates in its catalyst calendar for each verified company.